Extensive recent literature on drugs used to enhance cognitive functioning, reflects the growing social problem of dementia. Many clinical trials have been undertaken with variable success. In most cases the disorder studied has been Alzheimer's disease. The pharmacological approach has been designed to rectify the presumed pathophysiological processes characteristic of the condition. Agents tested include cerebral vasodilators, cerebral metabolic enhancers, nootropics, psychostimulants, neuropeptides and neurotransmitters with a special emphasis on drugs used to enhance cholinergic function. Ethical and practical issues concerning clinical drug trials in dementia will be discussed. © 1988, Canadian Neurological Sciences Federation. All rights reserved.
CITATION STYLE
Waters, C. (1988). Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer’s Disease. Canadian Journal of Neurological Sciences / Journal Canadien Des Sciences Neurologiques, 15(3), 249–256. https://doi.org/10.1017/S0317167100027694
Mendeley helps you to discover research relevant for your work.